The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cere
The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Fluoxetine
- Cisapride
- Prucalopride
Serotonin 4 (5-HT4) receptor agonist
What it measured
Main measures
- MRS: NAA and glutamaat
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: - age of 18-60 years Exclusion: - ECG with QT-lengthening
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To study the energy metabolism of the astrocytes in multiple sclerosis. We will investigate whether elevation of cAMP signaling (by fluoxetine, cisapride and prucalopride) in astrocytes of persons with MS is able to restore axonal metabolism and reduce glutamate levels in normal appearing white matter and gray matter.
Loading reviews and guidelines…
Related trials
- Amiloride Clinical Trial In Optic Neuritis
Phase 2 · Completed
Missed its main goal
- Combination of Antidepressants and Fingolimod Relapsing-remitting Mult
Phase 4 · Stopped early
Stopped
- The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Pa
Phase 2 · Status unknown
No results found
- Study on Cognitive Disorders of Multiple Sclerosis
Phase 3 · Completed
Missed its main goal
History
Started
Nov 2010